Lantheus Holdings, Inc. (LNTH), a leading entity in the radiopharmaceutical sector, announced on Wednesday that its Board of Directors has sanctioned a share repurchase program amounting to $250 million, to be executed over the forthcoming year.
The company intends to initiate this buyback in the fourth quarter, aiming to redistribute capital to shareholders throughout the next twelve months.
Brian Markison, the CEO of Lantheus, remarked, "Endowed with a robust financial foundation, and aligned with the Board's commitment to enhancing shareholder value, this share repurchase initiative underscores our confidence in Lantheus' ongoing leadership in radiopharmaceuticals and its capability to foster long-term, sustainable growth."
